MediWound (NASDAQ:MDWD), a biopharmaceutical developer focused on enzymatic therapeutics for tissue repair, reported fourth-quarter losses that were narrower than analysts had anticipated.
The Yavne, Israel-based company announced on Thursday a net loss of $7.2 million, or 56 cents per share, outperforming the 65-cent loss predicted by Wall Street.
While earnings provided a positive surprise, quarterly revenue of $1.9 million trailed the $2.1 million projected by analysts.
For the full year, the company posted a total loss of $23.9 million on revenue of $17 million.
Despite the revenue lag in the final period of the year, MediWound issued optimistic forward-looking guidance, projecting 2026 revenue between $24 million and $26 million.
The company continues to advance its clinical pipeline, including its Phase III VALUE trial for EscharEx, as it transitions toward larger-scale commercial readiness.